SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET. A live webcast of the event will be available in the Investors section of ...

FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0. ...

~ Provides 2026 Revenue Outlook ~ LONG ISLAND CITY, N.Y., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Steven Madden, Ltd. (Nasdaq: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided its 2026 revenue outlook. Amounts referred to as “Adjusted” are non-GAAP measures that exclude the items defined as “Non-GAAP Adjustments” in the “Non-GAAP Reconciliation” section. Fourth Q ...

JERICHO, N.Y., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) announced today that its management will present at the Citi 2026 Global Property CEO Conference on Tuesday, March 3, 2026. Event: Kimco Realty® Management Presentation When: Tuesday, March 3, 2026, from 2:10 PM – 2:45 PM, ET Live Webcast: Kimco Realty Management to Present at Citi Conference Audio from the webcast will be available on Kimco Realty’s investor relations website until June 2, 2026. About Kimco Realty® Kimco Realty® (NY ...

JERICHO, N.Y., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) announced today that its management will present at the Raymond James Institutional Investors Conference on Monday, March 2, 2026. Event: Kimco Realty® Management Presentation When: Monday, March 2, 2026, from 8:40 AM – 9:10 AM, ET Live Webcast: Kimco Realty Management to Present at Raymond James Conference Audio from the conference will be available on Kimco Realty’s investor relations website until May, 31, 2026. About Kimco Realty ...

Maintaining Full-Year 2026 Guidance, But Seeing Additional Earnings Pressure in 1Q26PERRYSBURG, Ohio, Feb. 25, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE John Haudrich, Chief Financial Officer of O-I Glass, Inc. (“O-I,” NYSE: OI), will present at the BofA Securities 2026 Global Agriculture and Materials Conference on Wednesday, February 25, 2026, at 10:30 a.m. ET. During the presentation, O-I will outline its strategy to enhance shareholder value through improved competitiveness, disciplined cost trans ...

Core Insights - Recursion has reached a pivotal moment, transitioning from demonstrating AI's role in drug discovery to showcasing an AI-native operating system that can generate clinical proof and sustainable value [3] - The company enters 2026 with five clinical programs advancing and over $500 million in milestone payments earned to date, reflecting a robust pipeline and disciplined execution strategy [3][6] Business Highlights - Recursion's pipeline is diversified, powered by its AI-native Recursion OS, with both wholly-owned and partnered programs [4] - The company achieved its first clinical validation of the Recursion OS in Familial Adenomatous Polyposis (FAP), with 75% of evaluable patients showing reductions in total polyp burden [6][9] - Recursion has received $134 million in milestone payments from its collaboration with Sanofi, with five discovery program packages accepted to date [6][14] Financial Performance - Total revenue for Q4 2025 was $35.5 million, a significant increase from $4.5 million in Q4 2024, driven by milestone payments and collaboration agreements [15] - Research and development expenses for Q4 2025 were $95.9 million, slightly lower than $98.3 million in Q4 2024, while total R&D expenses for the year were $475.3 million compared to $314.4 million in 2024 [15][22] - The net loss for Q4 2025 was $108.1 million, an improvement from a net loss of $178.9 million in Q4 2024, with a total net loss of $644.8 million for the year [15][22] Pipeline and Milestones - Recursion's pipeline includes several promising candidates, such as REC-4881 for FAP, REC-617 for advanced solid tumors, and REC-7735 for PI3Kα H1047R mutation [7][9] - Upcoming milestones include FDA engagement for REC-4881 and additional Phase 1/2 clinical data expected in 2026 [9][12] - The company anticipates further advancements in its partnered discovery programs, with potential for additional near-term milestones as programs progress [8][14] Cash Position - As of December 31, 2025, Recursion had cash and cash equivalents of $754 million, providing a runway into early 2028 without additional financing [6][15] - The company achieved a cash operating expense of approximately $399.2 million for 2025, reflecting improved operational efficiency [12][22]

Core Insights - Loblaw Companies Limited reported solid fourth quarter results for 2025, with a revenue increase of 11.3% to $16,382 million, driven by strong customer traffic and e-commerce growth [3][8][23] - The company continues to focus on strategic growth initiatives, including expanding its store network and enhancing its digital engagement platforms [19][21][22] Financial Performance - Revenue for the fourth quarter increased by $1,657 million, or 11.3%, with a comparable 12-week revenue growth of 3.5% [8][23] - Retail operating income rose by 43.0% to $1,134 million, while adjusted EBITDA increased by 11.3% to $1,775 million [8][23] - Net earnings available to common shareholders were $656 million, reflecting a 42.0% increase, with diluted net earnings per share rising by 44.7% to $0.55 [8][23] Sales Growth - Food Retail same-store sales increased by 1.5%, while Drug Retail same-store sales grew by 3.9% [8][23] - E-commerce sales saw a significant increase of 19.6%, highlighting the importance of omnichannel convenience for customers [3][8] Strategic Initiatives - The company opened 77 new stores in 2025 and ramped up its automated distribution centers to enhance operational efficiency [4][21][22] - Loblaw is focusing on its loyalty program, PC Optimum, to drive customer engagement and retention [19][21] Market Position - Loblaw's strong performance in the fourth quarter contributed to market share gains across its banners, supported by a focus on value, quality, and service [3][4] - The company is well-positioned to meet the evolving needs of Canadians, with a commitment to retail excellence and strategic investments for future growth [19][20]

Financial Performance - Golar LNG reported a Q4 2025 net income of $10.4 million, a 130% increase from Q4 2024, and a full-year net income of $66 million, up 29% year-over-year [1][4] - Total operating revenues for Q4 2025 reached $132.8 million, a 101% increase compared to Q4 2024, with year-to-date revenues of $393.5 million, reflecting a 51% increase [1][4] - Adjusted EBITDA for Q4 2025 was $91 million, a 54% increase from Q4 2024, and $265 million for the full year, a 10% increase [1][4] Operational Highlights - The company secured $14 billion in Adjusted EBITDA backlog through two 20-year contracts for FLNG Hilli and MKII FLNG with Southern Energy S.A. in Argentina [3][4] - FLNG Hilli exceeded its 2025 production target, while FLNG Gimi overproduced compared to its contractual commitments during Q4 2025 [4][9] - The construction of MKII FLNG is on schedule and on budget, with all conditions precedent for the contract with SESA satisfied [4][26] Financial Transactions - Golar executed $2.275 billion in new financing facilities during the year, including a $1.2 billion secured bank facility for FLNG Gimi [3][16] - The company entered the U.S. bond market with $500 million of 5-year senior unsecured notes at a 7.50% interest rate [4][15] - A share buyback program resulted in the repurchase and cancellation of 1.1 million shares at an average price of $37.76 per share, with $109 million remaining available [4][9] Liquidity and Debt - Total Golar Cash as of December 31, 2025, was $1.2 billion, while Golar's share of contractual debt was $2.7 billion, resulting in a net debt position of $1.5 billion [13][49] - The company has a significant liquidity release potential through debt refinancing alternatives, particularly for FLNG Hilli, which has an Adjusted EBITDA backlog of $5.7 billion [21][30] Market Position and Future Outlook - Golar is positioned as the only proven FLNG service provider globally, with strong operational uptime and capital efficiency [4][38] - The company anticipates continued strong demand for FLNG services, with plans to order a fourth FLNG unit once commercial terms mature [34][36] - Golar's 10% ownership in SESA provides additional commodity exposure, with potential upside linked to LNG prices [30][31]

Technip Energies (PARIS:TE), as leader of a joint venture (T.ENCCCGAC JV) with Consolidated Contractors Company (CCC) and Gulf Asia Contracting (GAC), has been awarded a major1 Engineering, Procurement, Construction and Commissioning (EPCC) contract by QatarEnergy for the onshore LNG facilities of the North Field West (NFW) project. This award covers the delivery of 2 mega trains, each with a capacity of 8 MTPA2 of liquefied natural gas, as a replication of the 2 trains under construction by Technip Energie ...